Crystagen

At Verified Peptides, we want to lead with an unusual and important disclosure for Crystagen: we found a genuine, unresolved inconsistency across commercial sources describing its basic chemical identity, and we have not been able to independently resolve it with confidence. Most vendor and "peptide guide" sources describe Crystagen as a single synthetic tripeptide with the sequence Glu-Asp-Pro (EDP), internally coded T-38 by Khavinson's institute, with a molecular weight cited in the range of approximately 345-359 g/mol and a molecular formula of C14H21N3O8 by some sources. However, at least one seller of the specifically branded Crystagen product describes its active ingredient as "peptide complex AS-6," listing proline, glutamic acid, and aspartic acid as its components without confirming they are joined into one specific bonded tripeptide sequence — language that reads more like Khavinson's natural "cytomax" complexes (such as Glandokort, also built on this site) than his single-sequence "cytogen" peptides.

We are disclosing this conflict directly rather than picking whichever description sounds more authoritative, because we think researchers deserve to know that a real ambiguity exists here, not a settled fact we are simply summarizing. A CAS registry number is explicitly reported as unassigned ("N/A") by at least one source we checked, and we could not locate a PubChem entry we could confidently match to this specific compound — both observations are at least as consistent with a natural, less rigorously characterized complex as with a fully defined single synthetic peptide.

Regardless of which structural description is correct, Crystagen is consistently attributed across sources to Khavinson's research program and consistently described as targeting thymic/immune tissue function, positioned within the same general "immunogeroprotective" research framework as several other Khavinson-associated peptides in this catalog.

This kind of source inconsistency is not unique to Crystagen in the broader commercial research-peptide space, but it is more pronounced here than for any other compound we have built in this Phase 4 batch. By comparison, Epithalon, Vilon, and Thymogen are described with a consistent single sequence, a consistent CAS number, and a consistent PubChem entry across essentially every source we checked. Crystagen's inconsistency — spanning its basic structural category, its exact molecular weight, and whether it even has an assigned CAS number — suggests either less rigorous independent characterization of this specific product, a genuinely more complex or variable underlying material, or some combination of the two, none of which we can resolve definitively from publicly available sources alone.

At Verified Peptides, we conducted a direct, multi-query search for PubMed-indexed primary research specifically naming "Crystagen" or "Cristagen" and located none. The specific claims repeated across commercial sources — genetic-level thymus stimulation, B-cell and T-cell activation, applications in acute infections and pre-surgical immune preparation — are consistently attributed to Khavinson's research program but are not, to our knowledge, traceable to a specific, independently checkable indexed publication under the Crystagen name itself.

We think it is important for researchers to understand what this means in combination with the classification ambiguity described above: Crystagen is a compound whose basic chemical structure is described inconsistently across the sources available to us, AND for which we could not locate a dedicated indexed primary study under either possible description. This places it, evidentially, in a similar position to Cardiogen (also built on this site, for which we located zero dedicated indexed studies), but with the added complication that even the compound's basic structural identity is not something we could confirm with confidence.

No FDA, EMA, or other Western regulatory body has evaluated or approved Crystagen for any indication. At Verified Peptides, we sell research-grade Crystagen strictly for laboratory research, and we think researchers evaluating this specific compound should treat both its structural identity and its functional claims as considerably less certain than most other compounds in this catalog, and should seek out primary Russian-language institute documentation directly if they want to resolve the classification question before designing research around it.

The rename from "Cristagen" to "Crystagen" (noted in this build's governing task list) may itself reflect the kind of inconsistent transliteration and naming common across Russian-to-English peptide product names in this general commercial space, where the same underlying Russian product name can appear spelled multiple ways across different vendors and translated summaries — a pattern that likely also contributes to the broader classification inconsistency we found for this specific compound.

A structurally related but genuinely distinct compound, Cortagen (Ala-Glu-Asp-Pro, AEDP), does have at least one dedicated indexed study (PMID 12420072) examining its effects on thymocyte blast transformation, in which it was reported to NOT produce a comitogenic effect in the specific assay tested — a real, honestly-reported negative finding for a related compound. Researchers should not read this as evidence about Crystagen itself, since Cortagen has an additional alanine residue and is a separate compound with its own distinct designation within Khavinson's catalog, but the naming and compositional similarity (both share the Glu-Asp-Pro backbone) is a genuine and easy source of confusion.

The inconsistency in how Crystagen's basic chemistry is described across sources — single tripeptide versus natural complex — is, in a sense, itself informative: it suggests that whatever due diligence has gone into characterizing and consistently marketing this specific compound has been less rigorous than for better-established Khavinson cytogens like Epithalon or Vilon, which are consistently described the same way (single defined sequence, consistent CAS number, consistent PubChem entry) across essentially every source we checked during this entire Phase 4 build.

At Verified Peptides, we require documentation of manufacturing and quality-control standards for research-grade Crystagen we offer, with a Certificate of Analysis (COA) available for each lot. Given the classification ambiguity described above, we think it is especially important for researchers to request and review the specific COA for any batch they receive, since standard single-compound purity metrics (such as HPLC purity against one target molecular weight) presuppose a single, defined molecular target — an assumption we cannot confidently make for this specific compound based on the sources available to us.

We source exclusively from manufacturers operating under quality-controlled systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers with a specific need to confirm Crystagen's exact structural identity before designing an experimental protocol around it should request detailed analytical documentation (mass spectrometry sequence confirmation, not just purity percentage) directly from their supplier.

Lyophilized Crystagen is typically stored at -20°C, protected from light and moisture, consistent with standard storage guidance for lyophilized peptide preparations generally. At Verified Peptides, we ship material with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with bacteriostatic water or another appropriate sterile diluent, solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation. As with other short peptides in this catalog, reconstituted solutions are generally less stable than the lyophilized form and more susceptible to degradation and microbial contamination with repeated freeze-thaw cycling.

Given the uncertainty around Crystagen's precise structural composition, researchers should treat general short-peptide storage principles as a reasonable but not compound-specifically validated guide, and follow whatever specific storage guidance is provided with each lot's own documentation.